Professional Documents
Culture Documents
Medical Device
Landscape
Transformation
22 June 2022
1
Each of us has a
crucial role in ensuring
that the next
generation is healthy,
well-educated, and
productive.
2
MoH is committed to implementing health system transformation
Six pillars of health transformation
Vision
In line with the President's vision to create healthy, productive, independent and just people
Improve maternal,
Health
children health, family Accelerate improvement Healthy Movement Strengthen health system
system Improve disease control
planning and of community nutrition Culture (GERMAS) and drug & food control
outcomes
reproductive health
a b c d a b
Population Education Primary prevention Secondary Improving Increasing access Improving Strengthening
6 main prevention capacity and and quality of resilience of emergency
7 main campaigns: adding the scope of response resilience
pillars immunization, Health screening for capability of secondary health pharma and med-
14 routine
balanced nutrition, 14 leading diseases primary care care devices sector national network of lab
immunization and to based surveillance,
sports, no-smoking causing death in Developing Puskesmas Constructing hospitals Local production of
movement, all regions in additional workers for
each age target, in 171 sub-districts, in eastern areas, 14 routine vaccines, emergency response,,
sanitation, disease Indonesia stunting screening, & provision of 40 mentoring network of 6 top 10 med, top 10 table top exercise of
screening, and improving ANC for crisis preparedness.
essential med, adding priority care, med-devices by
medical compliance maternal and baby health workers in partnership with world’s volume & by value.
health. primary care t op healt hcare cent ers.
Health Talent
4 Health financing 5 6 Health Technology
Transformation Transformation Transformation
Health financing regulation with 3 Adding med students quota, local and Development and usage of technology, digitalization,
goals: accessible, sufficient, and and bio-technology in health sector.
international scholarship, easy access for
sustainable; equitable allocation; abroad medical graduates for adaptation a Information b Biotechnology
and effective-efficient utilization process. technology
8
Pilar 3
Health System
Resilience
Local production of pharma
and medical devices and the
emergency response resilience
4
Strategy for the resilience of pharmaceutical, medical devices, and
emergency response
2022 2023 2024 2025
Vaccines 1. Measles
3. Hep B
4. Rotavirus
2. Rubella 5. HPV 7. IPV
3. Rotavirus 6. PCV 8. JE
Production of 7 out of 14 types of antigens for the routine 4. TBC
immunization vaccines and tuberculosis program
mRNA vaccine Viral vector vaccine
Mastery of viral-vector and nucleic acid based technologies
Technology transfer through B2B, international organization, and multilateral cooperation
Pharmaceutical
Insulin
1. Candesartan 3. Amlodipine 5. Cefixime
2. Bisoprolol 4. Lansoprazole 6. Ceftriaxone
Production of 6 out of 10 highest consumption pharmaceutical
raw materials / active pharmaceutical ingredients (API)
Plasma Derivatives
EPO, Insulin, m-Ab (Albumin, IVIg, F-VIII), m-
m-Ab (Tocilizumab),
Production of biopharmaceutical and plasma derivatives (Bevacizumab), St em
HyFC-EPO
Ab (Adalimumab,
Cell Rituximab, PD-1), R-
Insulin
5
Local production of top 10 medical devices by volume and
by value
16 out of 19 top value medical devices can be produced locally, while 3 are still dependent on import
No By Volume By Value
2 Intravascular administration set Cardiac monitor (including cardiotachometer and rate alarm)
6
Policy to promote the resiliency of pharmaceutical and medical
devices
Research & development Production Market protection
• Task force to develop R&D • Intervention through incentives • Substitution of imported products:
ecosystem and disincentives for pharma and Freezing imported products in the e-
medical devices industries catalog that can be produced locally
• Facilitate technology transfer and are able to meet national
• Simplification of permission demand
• Facilitate clinical trial for process
vaccine (especially Merah • Implementation of domestic
Putih Vaccine) • Facilitate testing and calibration component level / local content
performance and use of medical (TKDN) policy: prioritizing
• Facilitate clinical trial for devices pharmaceutical and medical devices
medical devices
product with high domestic
• Facilitate the change source component level / local content
of pharmaceutical raw (TKDN) in the procurement of goods
materials / active and services
pharmaceutical ingredient
(API)
• Implementation of Increased Use of
Domestic Product (P3DN) program
especially in the government / public
hospitals (vertical and regional) and
private hospitals
7
Regulatory
Convergence and
Harmonization
8
Strengthening regulatory capacity to ensure access to affordable medical
products that are safe, of good quality and effective
9
Regulation on Medical Device Sector
• Pre and Post Market Control
GDP
• Manufacturer License • Product License
• Distribution License
GMP
Enforcement
Sampling Monitoring Vigilance Advertising & audit
10
Regulation on Medical Device Sector
• Indonesia Medical Device Regulation Based on Regional and
Global Practices Clinical
Performance
& Regional and multilateral cooperation
Safety
AMDD Indonesia has
ratified
Quality ASEAN
GHWP Management MEDICAL
System DEVICE
Pre-Market DIRECTIVE
(AMDD). Priotity Working Area:
WHO, APEC, IMDRF Medical Devices : Pre-
Bilateral cooperation Market, Post-Market and
QMS
Post Market
Standards
Collaboration with
Bilateral Cooperation Asia, Middle East
and Africa through Collaboration with South East Asia countries for
GHWP. medical products with one of Working Group is Medical
• USA • India • Laos • China Device and IVD.
• Australia • Iran • PNG • Turkey
• Netherland • Colombia • Qatar • Vietnam
• Brunei Darussalam • SouthKorea • Singapore • Etc (MoU on progress)
• Denmark • Cuba • Timor Leste
11
Regulation on Medical Device Sector
• MD Classification HIGH RISK
D
C MODERATE
HIGH RISK
LOW
MODERATE
RISK
A
LOW RISK
Classification AMDD EU
(ASEAN MED DEV
DIRECTION)
Low risk A I
Low-Moderate risk B IIa
Risk Clasification is based on the
potency of risk that caused Moderate-High risk C IIb
High risk D III
12
Overview of Medical Device Registration
New Application
Applicant REGALKES
▪ Determine risk class of MD
▪ Submit medical device registration
application and upload the requirements
▪ PNBP (fee) payment
Fulfillment of
PB UMKU application Download
requirement in the
Yes
Ministry/Institution
EVALUATION Approved?
▪ Login with OSS-
(K/L) system Applicant
RBA username and No Medical device
password need additional data registered
▪ Submit PB UMKU
application Yes (product license)
Submit EVALUATION
additional data of additional Approved?
and
requirements data
No Rejection letter
Download
13
Medical Device Registration
Notification
Submitted by:
Distributor
Regular
Distribution License
• Class A in general
• Class B, C, D
• SLA>>
• Requirement >>
http://regalkes.kemkes.go.id/
14
MEDICAL DEVICE REGISTRATION Service Level Agreement (SLA) of
Indonesia Medical Device Classification MEDICAL DEVICES
New Registration
Medical devices risk Evaluation timeline
High Risk classification Medical (maximum of working days) Registration
Device
dermal filler, determines the Class Local Imported Fee
Class D breast implant, Product Product
registration IDR 1.500.000
HIGH IOL A 10 15
requirements that (±USD 105)
RISK IDR 3.000.000
has to be submitted B 20 30
(±USD 210)
to ensures the IDR 3.000.000
C 20 30
safety, quality and (±USD 210)
Class C ventilator, infusion IDR 5.000.000
set, mobile x-ray, efficacy/performanc D 30 45
(±USD 350)
MODERATE - HIGH
contact lens e of medical devices *1 USD = ± IDR 14300
RISK
Registration for renewal , variation,
or renewal with variation
Surgical apparel, Evaluation timeline
Class B (maximum of working days)
Registration Fee
electric hospital bed, Medical
LOW - MODERATE sphygmomanometer, Device Variation or
Renewal/ Renewal w/
RISK incubator Class Renewal renewal w/
Variation variation
variation
IDR 500.000 IDR 1.000.000
A 7 10
(± USD 35) (±USD 70)
IDR 1.000.000 IDR 1.500.000
B 7 10
Class A Gauze, manual (±USD 70) (±USD 105)
LOW RISK IDR 1.000.000 IDR 1.500.000
hospital bed, glove, C 7 10
(±USD 70) (±USD 105)
surgical instrument D 7 10
IDR 1.000.000 IDR 1.500.000
(±USD 70) (±USD 105)
17
NOTIFICATION
● Product license registration with notification
Medical device registration by notification
only applied to certain class A medical device
Arm sling Ice bag Ophthalmic eye shield
which is home-use and non sterile class A
Body waste
medical device that can be used independently Limb orthosis OTC Denture cleanser
receptacle
without any professional or special skill/ Cane Nipple shield Patient scale
healthcare professional assistance. Cane, crutch, and Medical adhesive tape Protective garment for
walker tips and pads. and adhesive bandage incontinence
● Notification also doesn’t apply to in vitro Nonresorbable
Medical disposable
diagnostic product. Mechanical wheelchair gauze/sponge for external
bedding
use
● Simplification of marketing authorization/ Crutch Mechanical Walker Stand-on patient scale
19
Guidance On Medical Device Registration
Risk Classification Tool – KMK 4475/2021 - related risk class Medical Device Product
SIKLARA and type of medical device Registration Guidelines
20
http://regalkes.kemkes.go.id/
21
Together we can
build a stronger and
healthier Indonesia
22
23